Hims & Hers Health, Inc. (NYSE: HIMS)

$27.76 ▼ -1.25 (-4.29%)

As of Apr 23, 2026 02:40 PM

Sector: Consumer Defensive Industry: Household & Personal Products CIK: 0001773751

Market Cap 6.33 Bn

P/E 49.34

P/S 2.70

Div. Yield 0.00

ROIC (Qtr) 0.19

Total Debt (Qtr) 3.65 Mn

Revenue Growth (1y) (Qtr) 28.41

Add ratio to table...

About

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform, transforming how customers fulfill their health needs. Launched in 2017, the company leverages a digital platform to provide access to treatments for a broad range of chronic conditions, including sexual health, hair loss, hormone health, weight loss, dermatology, and mental health. The platform also offers comprehensive laboratory testing services. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate,...

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform, transforming how customers fulfill their health needs. Launched in 2017, the company leverages a digital platform to provide access to treatments for a broad range of chronic conditions, including sexual health, hair loss, hormone health, weight loss, dermatology, and mental health. The platform also offers comprehensive laboratory testing services. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate, including through personalized treatment plans, with prescriptions fulfilled online through licensed pharmacies. Additionally, the company offers access to a range of non-prescription health and wellness products. Through its mobile applications, consumers can access educational programs, wellness content, community support, and other services that promote lifelong health and wellness. The company has facilitated over fifty million telehealth consultations, enabling greater access to high-quality, convenient, affordable, personalized care for people in the United States, Canada, the United Kingdom, and the European Union.

Hims & Hers Health, Inc. generates revenue through a combination of prescription medications, over-the-counter products, and subscription-based services. The company offers access to treatments for various chronic conditions, including sexual health, hair loss, hormone health, weight loss, dermatology, and mental health. Key products include prescription generic, brand-name, and compounded medications, as well as over-the-counter drug and device products, cosmetics, and supplement products. Many of the offerings are sold to customers on a subscription basis, providing a recurring revenue stream. The company also offers access to laboratory testing services to measure a broad set of biomarkers, supporting health assessment, early identification of potential risks, and ongoing clinical management by healthcare providers on the platform. The customer base includes individuals seeking convenient, affordable, and personalized healthcare solutions across multiple geographies, including the United States, Canada, the United Kingdom, and the European Union.

• Sexual Health: Hims & Hers provides treatments for sexual health conditions, including erectile dysfunction and other related issues. The platform offers access to prescription medications and non-prescription products aimed at improving sexual health and wellness. This segment caters to individuals seeking discreet and convenient solutions for sexual health concerns.

• Hair Loss: The company offers treatments for hair loss, including prescription medications and non-prescription products designed to promote hair growth and address hair loss concerns. This segment targets individuals experiencing hair thinning or loss, providing them with accessible and effective solutions.

• Hormone Health: Hims & Hers provides treatments for hormone-related conditions, such as testosterone support, menopause, and perimenopause. The platform offers access to prescription medications and non-prescription products aimed at balancing hormones and improving overall well-being. This segment serves individuals seeking hormone health solutions.

• Weight Loss: The company offers treatments for weight loss, including prescription medications and non-prescription products designed to support weight management. This segment caters to individuals looking for effective and convenient weight loss solutions.

• Dermatology: Hims & Hers provides treatments for dermatological conditions, including skin care products and prescription medications. This segment targets individuals seeking solutions for various skin concerns, such as acne, eczema, and other dermatological issues.

• Mental Health: The company offers treatments for mental health conditions, including access to healthcare professionals who can prescribe medications when appropriate. This segment serves individuals seeking mental health support and treatment.

• Comprehensive Laboratory Testing: Hims & Hers provides access to laboratory testing services to measure a broad set of biomarkers, supporting health assessment, early identification of potential risks, and ongoing clinical management by healthcare providers on the platform. This segment caters to individuals seeking comprehensive health assessments and monitoring.

Hims & Hers Health, Inc. operates in a competitive industry, facing competition from traditional healthcare providers, pharmacies, large retailers, and other telehealth platforms. Key competitors include traditional healthcare providers, pharmacies, and large retailers that sell non-prescription products. Within the direct-to-consumer healthcare space, the company competes with private organizations offering similar product offerings for consumers and similar pharmacological capabilities, including compounding capabilities. Additionally, Hims & Hers competes with certain traditional pharmaceutical companies that offer prescription products through direct-to-consumer or digitally enabled channels. The company's competitive advantages include its trusted brand, innovative products and services, leading technology, and clinical excellence. The platform offers a streamlined, personalized patient and clinician experience, including access to consistent follow-up care, facilitated by proprietary algorithms and a customizable and integrated technology stack. The company leverages insights and feedback from its platform and offerings to provide personalized prescription and non-prescription treatments designed to meet individual needs. The clinical excellence of the platform ensures consistency and quality, delivered by highly-trained licensed healthcare providers.

The customer base for Hims & Hers Health, Inc. includes individuals seeking convenient, affordable, and personalized healthcare solutions across multiple geographies, including the United States, Canada, the United Kingdom, and the European Union. The company's offerings cater to a diverse range of health and wellness needs, attracting customers looking for accessible and effective treatments for various conditions. The platform's focus on empowering consumers to feel great through the power of better health resonates with a broad audience, driving significant customer traffic and engagement.

Investment thesis

Bull case

Hims & Hers’ relentless verticalization of its compounding infrastructure, now exceeding one million square feet, signals a strategic pivot from merely providing generic solutions to becoming a fully integrated health delivery system. By controlling raw material sourcing, sterile manufacturing, and distribution, the company can rapidly scale new specialty products—such as its low‑testosterone and menopause lines—without the bottlenecks that external vendors impose. This end‑to‑end control not only lowers unit costs but also enhances quality assurance, positioning Hims as a more credible partner for larger health‑care players and institutional investors. The financial data, showing a 13% adjusted EBITDA margin and $78 million of adjusted EBITDA in Q3, indicates that these efficiencies are already materializing, providing a solid runway for future expansion.
The announced partnership pipeline with Novo Nordisk and Marriott Pharmaceuticals highlights a unique value proposition: access to patented therapies at scale through a consumer‑centric platform. Even as Novo has threatened litigation, Hims retains the capacity to negotiate future agreements that can bring Novo’s Wegovy injections and oral variants into its ecosystem, potentially expanding revenue streams in the highly lucrative obesity market. This symbiotic relationship, coupled with the company’s investment in GRAIL’s multi‑cancer early detection test, showcases a broader strategy to become a one‑stop shop for preventive care. The diversified product mix reduces reliance on any single category, mitigating the risk of a market shock in the weight‑loss segment.
The company’s aggressive customer acquisition strategy, driven by a marketing spend of 39% of revenue yet delivering a 6‑point lift in marketing efficiency, demonstrates a sustainable scale‑up model. The shift from on‑demand sexual health to daily personalized solutions has bolstered subscriber retention, reflected in the 85% retention target and an implied lifetime value that exceeds the cost of acquisition. A high retention rate enhances the predictability of recurring revenue and enables the firm to reallocate capital toward diagnostics and longevity, further expanding the total addressable market. The consistent marketing leverage suggests that the brand is maturing into a robust consumer health platform with strong network effects.
International expansion, catalyzed by the Zava acquisition, is a critical driver of growth beyond the United States. The acquisition provides an established clinician network and regulatory framework in the UK, Germany, France, Ireland, and Spain, enabling Hims to replicate its US business model in new markets. Early traction indicates that consumers globally value the same “high‑touch” model, implying that the company can rapidly capture market share in Canada and potentially in Latin America and Asia. Geographic diversification not only spreads political and economic risk but also taps into larger populations with high obesity and chronic disease prevalence, aligning with the company’s long‑term revenue targets of $6.5 billion by 2030.
The planned launch of whole‑body lab testing before year‑end serves as a catalyst for upselling high‑margin specialty care. By bundling diagnostics with treatment plans, Hims can create a virtuous cycle where data‑driven insights drive prescription of its own therapeutics, thereby increasing prescription volume and reinforcing patient dependence on the platform. The company’s verticalization of testing infrastructure and anticipated cost reductions will likely compress margins only modestly while significantly enhancing customer LTV. Early reports suggest that the diagnostic offering can be introduced at a fraction of the cost of traditional lab services, providing a competitive edge that is difficult for rivals to replicate.

Hims & Hers’ relentless verticalization of its compounding infrastructure, now exceeding one million square feet, signals a strategic pivot from merely providing generic solutions to becoming a fully integrated health delivery system. By controlling raw material sourcing, sterile manufacturing, and distribution, the company can rapidly scale new specialty products—such as its low‑testosterone and menopause lines—without the bottlenecks that external vendors impose. This end‑to‑end control not only lowers unit costs but also enhances quality assurance, positioning Hims as a more credible partner for larger health‑care players and institutional investors. The financial data, showing a 13% adjusted EBITDA margin and $78 million of adjusted EBITDA in Q3, indicates that these efficiencies are already materializing, providing a solid runway for future expansion.
The announced partnership pipeline with Novo Nordisk and Marriott Pharmaceuticals highlights a unique value proposition: access to patented therapies at scale through a consumer‑centric platform. Even as Novo has threatened litigation, Hims retains the capacity to negotiate future agreements that can bring Novo’s Wegovy injections and oral variants into its ecosystem, potentially expanding revenue streams in the highly lucrative obesity market. This symbiotic relationship, coupled with the company’s investment in GRAIL’s multi‑cancer early detection test, showcases a broader strategy to become a one‑stop shop for preventive care. The diversified product mix reduces reliance on any single category, mitigating the risk of a market shock in the weight‑loss segment.
The company’s aggressive customer acquisition strategy, driven by a marketing spend of 39% of revenue yet delivering a 6‑point lift in marketing efficiency, demonstrates a sustainable scale‑up model. The shift from on‑demand sexual health to daily personalized solutions has bolstered subscriber retention, reflected in the 85% retention target and an implied lifetime value that exceeds the cost of acquisition. A high retention rate enhances the predictability of recurring revenue and enables the firm to reallocate capital toward diagnostics and longevity, further expanding the total addressable market. The consistent marketing leverage suggests that the brand is maturing into a robust consumer health platform with strong network effects.
International expansion, catalyzed by the Zava acquisition, is a critical driver of growth beyond the United States. The acquisition provides an established clinician network and regulatory framework in the UK, Germany, France, Ireland, and Spain, enabling Hims to replicate its US business model in new markets. Early traction indicates that consumers globally value the same “high‑touch” model, implying that the company can rapidly capture market share in Canada and potentially in Latin America and Asia. Geographic diversification not only spreads political and economic risk but also taps into larger populations with high obesity and chronic disease prevalence, aligning with the company’s long‑term revenue targets of $6.5 billion by 2030.
The planned launch of whole‑body lab testing before year‑end serves as a catalyst for upselling high‑margin specialty care. By bundling diagnostics with treatment plans, Hims can create a virtuous cycle where data‑driven insights drive prescription of its own therapeutics, thereby increasing prescription volume and reinforcing patient dependence on the platform. The company’s verticalization of testing infrastructure and anticipated cost reductions will likely compress margins only modestly while significantly enhancing customer LTV. Early reports suggest that the diagnostic offering can be introduced at a fraction of the cost of traditional lab services, providing a competitive edge that is difficult for rivals to replicate.

Bear case

The company’s core legal exposure, manifested in Novo Nordisk’s patent‑infringement lawsuit and the FDA’s regulatory threat against its compounded GLP‑1 products, poses a material risk to its business model. The litigation could result in injunctions that prohibit Hims from selling its proprietary compounded versions of Wegovy, effectively eliminating a significant revenue driver in the obesity market. The legal costs, potential settlements, and possible injunctions would not only erode profitability but also damage the brand’s credibility among both consumers and regulatory bodies.
The FDA’s recent directive to restrict the use of GLP‑1 APIs in non‑FDA‑approved compounded drugs signals a tightening of regulatory oversight that could impact Hims’ entire compounding operation. This increased scrutiny may lead to costly compliance upgrades, potential recalls, and the loss of its “personalized” defense if the agency determines that the compounding is not truly individualized. The resulting uncertainty could deter patients, reduce marketing spend effectiveness, and push consumers toward established pharmaceutical competitors.
The company’s heavy reliance on the GLP‑1 segment for revenue growth is a concentration risk, especially as the market matures and competition intensifies. With Novo’s patent expiration approaching in 2032 and generic manufacturers poised to enter the market, Hims faces the dual threat of price erosion and a shift in consumer preference toward brand‑name drugs that offer proven efficacy and safety. The company's compounded products lack the extensive clinical data that brand‑name drugs possess, making it vulnerable to a credibility crisis if efficacy or safety concerns arise.
The rapid expansion into diagnostics and longevity, while potentially lucrative, introduces operational complexity that the company may not be fully equipped to manage. Scaling laboratory testing at a high volume requires rigorous quality control, regulatory approvals, and data integration capabilities that have yet to be proven at scale. Any lapses could trigger regulatory penalties, product recalls, and reputational harm that would ripple across the entire platform. The company’s current focus on compounding may divert critical resources from ensuring diagnostic compliance.
The aggressive marketing spend, though currently leveraged, carries a risk of diminishing returns as the market becomes saturated. The company’s marketing efficiency metric of 39% of revenue indicates significant spend relative to growth, and further expansion—especially into international markets—may dilute this efficiency. If retention does not improve commensurately, the cost of customer acquisition could rise, squeezing margins and limiting the company’s ability to invest in new specialties.

The company’s core legal exposure, manifested in Novo Nordisk’s patent‑infringement lawsuit and the FDA’s regulatory threat against its compounded GLP‑1 products, poses a material risk to its business model. The litigation could result in injunctions that prohibit Hims from selling its proprietary compounded versions of Wegovy, effectively eliminating a significant revenue driver in the obesity market. The legal costs, potential settlements, and possible injunctions would not only erode profitability but also damage the brand’s credibility among both consumers and regulatory bodies.
The FDA’s recent directive to restrict the use of GLP‑1 APIs in non‑FDA‑approved compounded drugs signals a tightening of regulatory oversight that could impact Hims’ entire compounding operation. This increased scrutiny may lead to costly compliance upgrades, potential recalls, and the loss of its “personalized” defense if the agency determines that the compounding is not truly individualized. The resulting uncertainty could deter patients, reduce marketing spend effectiveness, and push consumers toward established pharmaceutical competitors.
The company’s heavy reliance on the GLP‑1 segment for revenue growth is a concentration risk, especially as the market matures and competition intensifies. With Novo’s patent expiration approaching in 2032 and generic manufacturers poised to enter the market, Hims faces the dual threat of price erosion and a shift in consumer preference toward brand‑name drugs that offer proven efficacy and safety. The company's compounded products lack the extensive clinical data that brand‑name drugs possess, making it vulnerable to a credibility crisis if efficacy or safety concerns arise.
The rapid expansion into diagnostics and longevity, while potentially lucrative, introduces operational complexity that the company may not be fully equipped to manage. Scaling laboratory testing at a high volume requires rigorous quality control, regulatory approvals, and data integration capabilities that have yet to be proven at scale. Any lapses could trigger regulatory penalties, product recalls, and reputational harm that would ripple across the entire platform. The company’s current focus on compounding may divert critical resources from ensuring diagnostic compliance.
The aggressive marketing spend, though currently leveraged, carries a risk of diminishing returns as the market becomes saturated. The company’s marketing efficiency metric of 39% of revenue indicates significant spend relative to growth, and further expansion—especially into international markets—may dilute this efficiency. If retention does not improve commensurately, the cost of customer acquisition could rise, squeezing margins and limiting the company’s ability to invest in new specialties.

Geographical Breakdown of Revenue (2025)

Peer comparison

Companies in the Household & Personal Products

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	PG	PROCTER & GAMBLE Co	341.29 Bn	21.12	4.00	36.64 Bn
2	UL	Unilever Plc	146.24 Bn	11.76	2.56	32.92 Bn
3	CL	Colgate Palmolive Co	67.80 Bn	31.76	3.33	6.87 Bn
4	KVUE	Kenvue Inc.	33.52 Bn	22.42	2.22	8.52 Bn
5	KMB	Kimberly Clark Corp	32.50 Bn	18.17	1.98	7.17 Bn
6	EL	Estee Lauder Companies Inc	27.54 Bn	-152.10	1.88	7.32 Bn
7	CHD	Church & Dwight Co Inc /De/	22.98 Bn	31.15	3.70	2.38 Bn
8	CLX	Clorox Co /De/	11.87 Bn	15.90	1.76	2.49 Bn

Research Tools